Overview

Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.

Phase:

Phase 1

Details

Lead Sponsor:

Cephalon

Treatments:

Cisplatin
Gemcitabine